Summary basis of decision for Xalkori

Health Canada has issued a Notice of Compliance under the Notice of Compliance with Conditions (NOC/c) Guidance to Pfizer Canada Inc., for the drug product Xalkori. Xalkori contains the medicinal ingredient crizotinib which is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Xalkori is indicated as monotherapy for use in patients with ALK-positive advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). Read more here.